GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. METHODS/DESIGN: GA101 (o...

Descripción completa

Detalles Bibliográficos
Autores principales: Oughton, Jamie B., Collett, Laura, Howard, Dena R., Hockaday, Anna, Munir, Talha, McMahon, Kathryn, McParland, Lucy, Dimbleby, Claire, Phillips, David, Rawstron, Andy C., Hillmen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530563/
https://www.ncbi.nlm.nih.gov/pubmed/28747208
http://dx.doi.org/10.1186/s13063-017-2107-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530563/
https://www.ncbi.nlm.nih.gov/pubmed/28747208
http://dx.doi.org/10.1186/s13063-017-2107-0

Ejemplares similares